Fumio Ishida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fumio Ishida has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Shin-Ei Kudo
Digestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Japan
8 shared publications - Masashi Misawa
Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
6 shared publications - Toyoki Kudo
Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
5 shared publications - Hideyuki Miyachi
Digestive Disease Center Showa University Northern Yokohama Hospital Yokohama Kanagawa Japan
4 shared publications - Kunihiko Wakamura
Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
4 shared publications - Yuichi Mori
Department of Transplantation Medicine, Gastroenterology Section, Oslo University Hospital, Oslo, Norway
4 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 776-784
Colitis-associated colorectal neoplasia in ulcerative colitis with primary sclerosing cholangitis: a nationwide study
Background/Aims: Ulcerative colitis (UC)-associated colorectal neoplasia (UCAN) in patients with UC and primary sclerosing cholangitis (PSC) has not been studied well in Japan. This retrospective study examined the clinicopathological features and prognosis of UCAN in patients with PSC-UC. Methods: A total of 808 patients with UCAN were enrolled from 1983 to 2020 and categorized into PSC (PSC-UCAN, n = 26) and no PSC (UCAN-alone, n = 782) groups. Clinicopathological features were compared between the 2 groups, and the 10-year overall survival (OS) and cancer-specific survival (CSS) were analyzed. Results: The PSC-UCAN group had a shorter UC duration before UCAN diagnosis (12.8 years vs. 16.9 years, P= 0.044), were younger at UCAN diagnosis (47.8 years vs. 53.3 years, P= 0.046), and developed UCAN more frequently in the right-sided colon (34.6% vs. 15.9%, P= 0.028) than the UCAN-alone group. The PSC-UCAN group showed a trend toward a lower proportion of high-grade dysplasia (19.2% vs. 30.7%) and a higher proportion of early-stage cancers (53.9% vs. 31.2%). The 10-year OS (64.6% vs. 79.3%, P=0.080) and CSS (80.8% vs. 83.9%, P=0.60) were comparable. Conclusions: Patients with PSC-UCAN showed earlier and younger development of UCAN than patients with only UCAN, with a high prevalence in the right-sided colon. Early-stage cancer was more frequently observed in the PSC-UCAN group, despite the shorter duration of UC. Patients with PSC-UC probably benefit from early initiation of surveillance colonoscopy.
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 776-784
Open AccessColitis-associated colorectal neoplasia in ulcerative colitis with primary sclerosing cholangitis: a nationwide study
Background/Aims: Ulcerative colitis (UC)-associated colorectal neoplasia (UCAN) in patients with UC and primary sclerosing cholangitis (PSC) has not been studied well in Japan. This retrospective study examined the clinicopathological features and prognosis of UCAN in patients with PSC-UC. Methods: A total of 808 patients with UCAN were enrolled from 1983 to 2020 and categorized into PSC (PSC-UCAN, n = 26) and no PSC (UCAN-alone, n = 782) groups. Clinicopathological features were compared between the 2 groups, and the 10-year overall survival (OS) and cancer-specific survival (CSS) were analyzed. Results: The PSC-UCAN group had a shorter UC duration before UCAN diagnosis (12.8 years vs. 16.9 years, P= 0.044), were younger at UCAN diagnosis (47.8 years vs. 53.3 years, P= 0.046), and developed UCAN more frequently in the right-sided colon (34.6% vs. 15.9%, P= 0.028) than the UCAN-alone group. The PSC-UCAN group showed a trend toward a lower proportion of high-grade dysplasia (19.2% vs. 30.7%) and a higher proportion of early-stage cancers (53.9% vs. 31.2%). The 10-year OS (64.6% vs. 79.3%, P=0.080) and CSS (80.8% vs. 83.9%, P=0.60) were comparable. Conclusions: Patients with PSC-UCAN showed earlier and younger development of UCAN than patients with only UCAN, with a high prevalence in the right-sided colon. Early-stage cancer was more frequently observed in the PSC-UCAN group, despite the shorter duration of UC. Patients with PSC-UC probably benefit from early initiation of surveillance colonoscopy.
- 9 June 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 97 (6) , AB533-AB534
CLINICAL AND PATHOLOGICAL FEATURES OF DEPRESSED-TYPE COLORECTAL NEOPLASM
- 9 June 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 97 (6) , AB533-AB534
CLINICAL AND PATHOLOGICAL FEATURES OF DEPRESSED-TYPE COLORECTAL NEOPLASM
- 7 June 2022
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 95 (6) , AB176
MOLECULAR AND CLINICOPATHOLOGICAL FEATURES OF DEPRESSED T2 COLORECTAL CANCER BASED ON CMS CLASSIFICATION
- 7 June 2022
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 95 (6) , AB176
MOLECULAR AND CLINICOPATHOLOGICAL FEATURES OF DEPRESSED T2 COLORECTAL CANCER BASED ON CMS CLASSIFICATION
- 7 September 2021
- Published by Springer Nature in Surgical Endoscopy
- Vol. 36 (6) , 3985-3993
Impact of non-curative endoscopic submucosal dissection on short- and long-term outcome of subsequent laparoscopic gastrectomy for pT1 gastric cancer
Background The feasibility and oncological safety of non-curative endoscopic submucosal dissection (ESD) prior to additional gastrectomy for early gastric cancer (EGC) are still unclear. The aim of this study was to evaluate the impact of non-curative ESD on short- and long-term outcomes of subsequent laparoscopic gastrectomy (LG) for pathological T1 (pT1) EGC. Methods We retrospectively investigated 422 patients who underwent LG for pT1 EGC between January 2007 and December 2017 at our center. Eighty-five of these patients underwent ESD with curative intent before surgery. Using propensity-score matching for sex, age, body mass index, American society of anesthesiologists score, history of previous abdominal surgery, tumor location, mucosal/submucosal infiltration, histology, lymph node metastasis, extent of lymph node dissection, operative method, lymphatic invasion, and venous invasion, the clinicopathologic and survival data of these patients were compared. Results The median follow-up period was 60 (range 2–168) months. Using propensity-score matching from a total of 422 patients, 75 patients were selected in the Non-ESD and the ESD cohorts each. There were no significant differences in terms of characteristics and clinicopathological findings between the two groups. Furthermore, there were no significant differences in postoperative morbidity (13.3% vs. 17.3%; P = 0.497) and mortality (1.3% vs. 0%; P = 0.316). Both the 5-year overall survival ratio (88.8% vs. 86.9%; P = 0.757) and 5-year disease-specific survival ratio (97.1% vs. 98.4%; P = 0.333) were similar in the two groups. Conclusion Short- and long-term outcomes of LG in patients with pT1 EGC are not related to preoperative ESD history. Even for non-curative resections, ESD prior to surgery is feasible in terms of oncological and surgical outcomes in pT1 EGC.
- 7 September 2021
- Published by Springer Nature in Surgical Endoscopy
- Vol. 36 (6) , 3985-3993
Impact of non-curative endoscopic submucosal dissection on short- and long-term outcome of subsequent laparoscopic gastrectomy for pT1 gastric cancer
Background The feasibility and oncological safety of non-curative endoscopic submucosal dissection (ESD) prior to additional gastrectomy for early gastric cancer (EGC) are still unclear. The aim of this study was to evaluate the impact of non-curative ESD on short- and long-term outcomes of subsequent laparoscopic gastrectomy (LG) for pathological T1 (pT1) EGC. Methods We retrospectively investigated 422 patients who underwent LG for pT1 EGC between January 2007 and December 2017 at our center. Eighty-five of these patients underwent ESD with curative intent before surgery. Using propensity-score matching for sex, age, body mass index, American society of anesthesiologists score, history of previous abdominal surgery, tumor location, mucosal/submucosal infiltration, histology, lymph node metastasis, extent of lymph node dissection, operative method, lymphatic invasion, and venous invasion, the clinicopathologic and survival data of these patients were compared. Results The median follow-up period was 60 (range 2–168) months. Using propensity-score matching from a total of 422 patients, 75 patients were selected in the Non-ESD and the ESD cohorts each. There were no significant differences in terms of characteristics and clinicopathological findings between the two groups. Furthermore, there were no significant differences in postoperative morbidity (13.3% vs. 17.3%; P = 0.497) and mortality (1.3% vs. 0%; P = 0.316). Both the 5-year overall survival ratio (88.8% vs. 86.9%; P = 0.757) and 5-year disease-specific survival ratio (97.1% vs. 98.4%; P = 0.333) were similar in the two groups. Conclusion Short- and long-term outcomes of LG in patients with pT1 EGC are not related to preoperative ESD history. Even for non-curative resections, ESD prior to surgery is feasible in terms of oncological and surgical outcomes in pT1 EGC.
- Open Access
- 30 July 2021
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 54 (4) , 455-463
Clinical Efficacy of Endocytoscopy for Gastrointestinal Endoscopy
Endocytoscopy (EC) is a contact-type optical endoscope that allows in vivo cellular observation during gastrointestinal endoscopy and is now commercially available not only in Japan but also in Asian, European Union, and Middle Eastern countries. EC helps conduct a highly accurate pathological prediction without biopsy. Initially, EC was reported to be effective for esophageal diseases. Subsequently, its efficacy for stomach and colorectal diseases has been reported. In this narrative review, we searched for clinical studies that investigated the efficacy of EC. EC seems to accurately diagnose gastrointestinal diseases without biopsy. Most of the studies aimed to clarify the relationship between endocytoscopic findings of gastrointestinal neoplasia and pathological diagnosis. Some studies have investigated non-epithelial lesions or diseases, such as inflammatory bowel disease or infectious diseases. However, there are few high-level pieces of evidence, such as randomized trials; thus, further studies are needed.
- 30 July 2021
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 54 (4) , 455-463
Open AccessClinical Efficacy of Endocytoscopy for Gastrointestinal Endoscopy
Endocytoscopy (EC) is a contact-type optical endoscope that allows in vivo cellular observation during gastrointestinal endoscopy and is now commercially available not only in Japan but also in Asian, European Union, and Middle Eastern countries. EC helps conduct a highly accurate pathological prediction without biopsy. Initially, EC was reported to be effective for esophageal diseases. Subsequently, its efficacy for stomach and colorectal diseases has been reported. In this narrative review, we searched for clinical studies that investigated the efficacy of EC. EC seems to accurately diagnose gastrointestinal diseases without biopsy. Most of the studies aimed to clarify the relationship between endocytoscopic findings of gastrointestinal neoplasia and pathological diagnosis. Some studies have investigated non-epithelial lesions or diseases, such as inflammatory bowel disease or infectious diseases. However, there are few high-level pieces of evidence, such as randomized trials; thus, further studies are needed.
- 1 March 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (4) , 1075-1084.e2
Artificial Intelligence System to Determine Risk of T1 Colorectal Cancer Metastasis to Lymph Node
- 1 March 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (4) , 1075-1084.e2
Artificial Intelligence System to Determine Risk of T1 Colorectal Cancer Metastasis to Lymph Node
- Open Access
- 28 September 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (6) , 7264-7270
Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion
With recent advances in endoscopic treatment, many T1 colorectal carcinomas (CRCs) are resected endoscopically with a negative margin. However, some lesions exhibit skip lymphovascular invasion (SLVI), which is defined as the discontinuous foci of the tumor cells within the colon wall. The aim of the present study was to reveal the clinicopathological features of T1 CRCs with SLVI and validate the Japanese guidelines regarding SLVI. A total of 741 patients with T1 CRCs that were resected surgically between April 2001 and October 2016 in our hospital were divided into two groups: With SLVI and without SLVI. Clinicopathological features compared between the two groups were patient's gender, age, tumor size, location, morphology, lymphovascular invasion, tumor differentiation, tumor budding and lymph node metastasis. The incidence of T1 CRCs with SLVI was 0.9% (7/741). All cases with SLVI were found in the sigmoid colon or rectum. T1 CRCs with SLVI showed significantly higher rates of lymphovascular invasion than those without SLVI (P<0.01). In conclusion, lymphovascular invasion was a significant risk factor for SLVI in T1 CRCs, and for which surgical colectomy was necessary. The Japanese guidelines are appropriate regarding SLVI. Registered in the University Hospital Medical Network Clinical Trials Registry (UMIN000027097).
- 28 September 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (6) , 7264-7270
Open AccessClinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion
With recent advances in endoscopic treatment, many T1 colorectal carcinomas (CRCs) are resected endoscopically with a negative margin. However, some lesions exhibit skip lymphovascular invasion (SLVI), which is defined as the discontinuous foci of the tumor cells within the colon wall. The aim of the present study was to reveal the clinicopathological features of T1 CRCs with SLVI and validate the Japanese guidelines regarding SLVI. A total of 741 patients with T1 CRCs that were resected surgically between April 2001 and October 2016 in our hospital were divided into two groups: With SLVI and without SLVI. Clinicopathological features compared between the two groups were patient's gender, age, tumor size, location, morphology, lymphovascular invasion, tumor differentiation, tumor budding and lymph node metastasis. The incidence of T1 CRCs with SLVI was 0.9% (7/741). All cases with SLVI were found in the sigmoid colon or rectum. T1 CRCs with SLVI showed significantly higher rates of lymphovascular invasion than those without SLVI (P<0.01). In conclusion, lymphovascular invasion was a significant risk factor for SLVI in T1 CRCs, and for which surgical colectomy was necessary. The Japanese guidelines are appropriate regarding SLVI. Registered in the University Hospital Medical Network Clinical Trials Registry (UMIN000027097).
- Open Access
- 1 May 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (5) , AB154
575 Narrow-Band Imaging Efficiency for Evaluation of Mucosal Healing/ Relapse of Ulcerative colitis
- 1 May 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (5) , AB154
Open Access575 Narrow-Band Imaging Efficiency for Evaluation of Mucosal Healing/ Relapse of Ulcerative colitis
- 1 November 2015
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 82 (5) , 912-923
Endocytoscopic microvasculature evaluation is a reliable new diagnostic method for colorectal lesions (with video)
- 1 November 2015
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 82 (5) , 912-923
Endocytoscopic microvasculature evaluation is a reliable new diagnostic method for colorectal lesions (with video)
- Open Access
- 1 January 2012
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 73 (11) , 2989-2993
A case of retroperitoneal dedifferentiated liposarcoma with leiomyosarcoma and osteosarcoma components
症例は50歳,男性.左側腹部痛を主訴に前医を受診し,同部に腫瘤を指摘され紹介となった.初診時に左下腹部に圧痛を伴う可動性不良な腫瘤を触知した.血液生化学検査では炎症反応の上昇と軽度貧血を認めた.CTでは下行結腸背側に手拳大の腫瘍を認め,内部は均一で一部に石灰化を伴っていた.MRIではT1強調・T2強調像で腫瘍は不均一な高信号を示した.後腹膜腫瘍と診断し,下行結腸と一塊に腫瘍を切除した.腫瘍は10.5×7.0×7.0cm,割面は充実性で白色調の部位と黄色調の部位が混在していた.病理組織学検査では紡錘形細胞が車軸状に増殖する像を認め,悪性線維組織球腫に類似した所見であった.CDK4およびMDM2が陽性で,腫瘍内には骨肉腫と平滑筋肉種の成分も認め,骨肉腫と平滑筋肉腫への分化を示す脱分極型脂肪肉腫と診断した.
- 1 January 2012
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 73 (11) , 2989-2993
Open AccessA case of retroperitoneal dedifferentiated liposarcoma with leiomyosarcoma and osteosarcoma components
症例は50歳,男性.左側腹部痛を主訴に前医を受診し,同部に腫瘤を指摘され紹介となった.初診時に左下腹部に圧痛を伴う可動性不良な腫瘤を触知した.血液生化学検査では炎症反応の上昇と軽度貧血を認めた.CTでは下行結腸背側に手拳大の腫瘍を認め,内部は均一で一部に石灰化を伴っていた.MRIではT1強調・T2強調像で腫瘍は不均一な高信号を示した.後腹膜腫瘍と診断し,下行結腸と一塊に腫瘍を切除した.腫瘍は10.5×7.0×7.0cm,割面は充実性で白色調の部位と黄色調の部位が混在していた.病理組織学検査では紡錘形細胞が車軸状に増殖する像を認め,悪性線維組織球腫に類似した所見であった.CDK4およびMDM2が陽性で,腫瘍内には骨肉腫と平滑筋肉種の成分も認め,骨肉腫と平滑筋肉腫への分化を示す脱分極型脂肪肉腫と診断した.